- Report
- August 2023
- 70 Pages
Spain
From €4227EUR$4,750USD£3,628GBP
- Report
- October 2022
- 70 Pages
Africa
From €4227EUR$4,750USD£3,628GBP
- Report
- February 2024
- 181 Pages
Europe
From €4227EUR$4,750USD£3,628GBP
- Report
- August 2026
- 160 Pages
From €2954EUR$3,320USD£2,536GBP
€3693EUR$4,150USD£3,170GBP
- Report
- October 2022
- 177 Pages
From €3070EUR$3,450USD£2,635GBP
- Report
- October 2022
- 174 Pages
North America
From €3070EUR$3,450USD£2,635GBP
- Report
- October 2022
- 181 Pages
Middle East, Africa
From €3070EUR$3,450USD£2,635GBP
- Report
- October 2022
- 205 Pages
Asia Pacific
From €3070EUR$3,450USD£2,635GBP
Xultophy is a market of endocrine and metabolic disorder drugs. It is a combination of insulin degludec and liraglutide, two drugs used to treat type 2 diabetes. Xultophy is designed to help people with type 2 diabetes achieve better glycemic control with fewer injections and fewer side effects. It is a once-daily injection that helps to reduce the risk of hypoglycemia and weight gain. Xultophy is also used to reduce the risk of cardiovascular events in people with type 2 diabetes.
Xultophy is a relatively new market, but it is growing rapidly. It is becoming increasingly popular among people with type 2 diabetes, as it offers a convenient and effective way to manage their condition.
Companies in the Xultophy market include Novo Nordisk, Eli Lilly, Sanofi, and Merck. Show Less Read more
